Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.

Autor: Arribas JR; Infectious Diseases Unit, Hospital Universitario La Paz-IdiPAZ, Madrid., Bhagani S; Department of Infectious Diseases, Royal Free Hospital, London., Lobo SM; Intensive Care Division, Hospital de Base, Faculdade de Medicina de São José do Rio Preto, Brazil., Khaertynova I; Republican Clinical Infectious Diseases Hospital n.a. A.F. Agafonov, Kazan, Russian Federation., Mateu L; Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, Barcelona., Fishchuk R; Central City Clinical Hospital of Ivano-Frankivsk City Council, Ivano-Frankivsk, Ukraine., Park WY; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington/Valley Medical Center, Renton, WA., Hussein K; Infection Control Unit, Rambam Healthcare Campus, Haifa, Israel., Kim SW; Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Ghosn J; Infectious and Tropical Diseases Department, Assistance Publique-Hôpitaux de Paris Bichat-Claude Bernard Hospital, Paris.; Institut National de la Santé et de la Recherche Médicale, UMR 1137 'Infection, Antimicrobial, Modeling, Evolution', Université de Paris, Paris., Brown ML; Merck & Co., Inc, Kenilworth, NJ., Zhang Y; Merck & Co., Inc, Kenilworth, NJ., Gao W; Merck & Co., Inc, Kenilworth, NJ., Assaid C; Merck & Co., Inc, Kenilworth, NJ., Grobler JA; Merck & Co., Inc, Kenilworth, NJ., Strizki J; Merck & Co., Inc, Kenilworth, NJ., Vesnesky M; Merck & Co., Inc, Kenilworth, NJ., Paschke A; Merck & Co., Inc, Kenilworth, NJ., Butterton JR; Merck & Co., Inc, Kenilworth, NJ., De Anda C; Merck & Co., Inc, Kenilworth, NJ.

Publikováno v: NEJM evidence [NEJM Evid] 2022 Feb; Vol. 1 (2), pp. EVIDoa2100044. Date of Electronic Publication: 2021 Dec 16.